Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
A 2:1:1 mixture of: trisodium N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-6''-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'-azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate
EC number: 402-850-1 | CAS number: - NOIR SANDODERM HH 1050; SANDODERM BLACK HH 1050; SANDODERM BLACK R; SANDODERM BLACK R CONC.; SANDODERM SCHWARZ R; SANDODERM SCHWARZ R KONZ.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
NOAEL (oral, rat female, 51 days) = 100 mg/kg bw/day
NOAEL (oral, rat male, 30 days) = 300 mg/kg bw/day
NOAEL (oral, rat, 28 days) = 200 mg/kg bw/day
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The repeated dose toxicity of the
substance was evaluated in a subacute 28-day oral toxicity study
according to the OECD Guideline 407 (1981) and method B.7 of the
Directive 84/449 EEC. The substance was administered daily by oral
gavage to SPF-bred Wistar rats of both sexes for a period of 28 days.
Test animals were randomly assigned to dose levels of 50, 200 and 1000
mg/kg bw/day and a control group which received only the vehicle
(carboxymethyl cellulose (4 %) in distilled water) (5 males and 5
females per group).
Observations for mortality and clinical signs were recorded daily; food
consumption and body weights were measured weekly. At four weeks,
ophthalmic examinations, blood samples for haematology and clinical
biochemistry, and urinalyses were performed. All test animals were
sacrificed at four weeks; at necropsy, organ weights were recorded and
macroscopic and microscopic histopathologic examinations were performed.
Females administered the highest dose recorded a slight decrease in
erythrocyte count, haemoglobin concentration and haematocrit value;
males administered the highest dose recorded a slight increase in
phosphorus and potassium. Both males and females administered the
highest dose recorded a moderate increase in urobilinogen which was
attributed to direct interaction with urine discolouration; however this
finding was considered adaptive and not of toxicological significance.
A significant increase in absolute kidney weights was observed among
males administered with 1000 mg/kg bw/day and females administered 200
mg/kg bw/day; and increased kidney to body weight ratios were observed
among females administered 50 and 200 mg/kg bw/day, however these
findings were considered to be of a spontaneous nature and not related
to treatment.
Macroscopic pathology findings included discolouration. Faeces and
gastrointestinal contents of most test animals in groups administered
200 and 1000 mg/kg bw/day were discoloured black between day 7 and the
end of treatment period. Black-brown foci in the lungs were observed in
2, 4 and 1 test animals from dosage levels 50, 200 and 1000 mg/kg
bw/day, respectively, however a dose-response relationship cannot be
established as incidence did not increase with dose. Mesenteric lymph
nodes displayed black-brown discolouration in one test animal which
received 200 mg/kg bw/day, and 7 which received 1000 mg/kg bw/day,
however these findings were considered to be of a spontaneous nature and
common among rats of this strain and age.
No treatment-related histopathological findings were recorded, however a
spurious amount of brownish pigment was found within macrophages in the
lung and mesenteric lymph nodes of some rates which was attributed to
accidental inhalation of the substance.
Based on the results observed, the NOAEL for the substance in male and
female rats is 200 mg/kg bw/day. Therefore, the lowest adverse effect
level (LOAEL) can be considered to be 1000 mg/kg bw/day.
Further data for general toxixcity is available from the screening test performed according to the OECD Guideline 421 (2016). Four groups containing 10 male and 10 female rats each were administered the test item in water softened by reverse osmosis (10 mL/kg of body weight) for 30 days (males) and at least 51 days (females). The test item was given to Sprague Dawley rats by oral administration (gavage) at dosages of 100, 300 and 1000 mg/kg/day. The control group received only the vehicle.
Non pregnant females and females with total litter loss were dosed up to the day before necropsy. The following investigations for general toxiccity on parental animals were performed in all groups: mortality check, clinical signs, body weight, body weight gain, food consumption and thyroid hormone determination only for males, macroscopic observations, organ weights. The histopathological evaluation was performed on the following organs/tissues: adrenal glands, epididymides, lungs, cervical and mesenteric lymph nodes, kidneys, liver,mammary gland, ovaries with oviducts, seminal vesicles with coagulating glands, testes, thyroid, uterus, cervix and vagina performed on all males and females from the control and high dose groups, as well as on all abnormalities detected during post mortem observation at the end of the treatment period. On the basis of treatment-related findings detected in the mesenteric lymph nodes and lungs of high dose treated animals of both sexes, the histopathological evaluation of these organs was extended to the low and middose animals of both sexes.
No mortality occurred during the study. The only clinical sign recorded during the treatment period was black staining on the tail (slight to marked) in all treated males and in females (slight to moderate) receiving the dose level ≥300 mg/kg/day. No adverse effects were observed in body weight or body weight gain of treated animals compared to control group. Food consumption of parental animals of both sexes was unaffected by treatment. Statistically significant increases of triiodothyronine and thyroxine were recorded in males dosed at 1000 mg/kg/day (46 % and 12 %, respectively). Similar increases were also recorded in some animals receiving 100 and 300 mg/kg/day, with no statistical significance nor clear dose-relation. Since changes were of low severity, with no dose-relation nor concurrent alteration of thyroid stimulating hormone, the above increases were considered to be of no toxicological relevance. No relevant changes were observed on terminal body weight, absolute and relative organ weights of treated animals, when compared to the controls.
An increased incidence of dark colour and/or areas of cervical and mesenteric lymph nodes, lungs and intestinal tract (caecum, colon, ileum and rectum) were noted in treated animals of both sexes. An increased incidence of reduced size of thymus was observed in high dose treated females, when compared to the controls.
Treatment-related lesions were noted in mesenteric lymph nodes of males and females receiving test item at 1000 mg/kg/day, in the lungs of males dosed at 1000 mg/kg/day and in females dosed at ≥300 mg/kg/day.
The findings consisted in the presence of black pigment laden macrophages in the mesenteric lymph nodes in all high dose males and females, and intracytoplasmic black granular pigment in the alveolar macrophages, associated or not with chronic inflammatory reactions in the lungs reported in males dosed at 1000 mg/kg/day and females dosed at ≥300 mg/kg/day.
Therefore, the NOAEL (No Observed Adverse Effect Level) for general toxicity was considered to be 300 mg/kg/day for males and 100 mg/kg/day for females, based on the results of this study.
The NOAEL determined for general toxicity in parental females during the OECD 421 (51 days, 100 mg/kg bw day) is selected as the most representative starting dose based on exposure route, study duration, presence of adverse effects, parameters observed. In addition, it is the lowest available value obtained in the available experimental studies. Therefore, it is used as key value for Chemical Safety Assessment .
Justification for classification or non-classification
According to the CLP Regulation (EC) no. 1272/2008, substances are classified as specific target organ toxicants following repeated exposure, and are placed in one of two categories, depending upon the nature and severity of the effect(s) observed.
Substances that have produced significant toxicity in humans or that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to produce significant toxicity in humans following repeated exposure, are classified in Category 1 for target organ toxicity (repeated exposure). Classification in Category 1 is applicable when significant toxic effects are observed in a 90-day repeated-dose animal study at low concentrations (< 10 mg/kg bw/day in oral studies, and < 20 mg/kg bw/day in dermal studies) (CLP Regulation (EC) no. 1272/2008: Annex 1, Part 3, Table 3.9.2).
Substances which can be presumed to have the potential to be harmful to human health following repeated exposure, based on evidence from animal studies, are classified in Category 2. Classification in Category 2 is applicable when significant toxic effects are observed in a 90-day repeated-dose animal study at generally moderate exposure concentrations (10 to 100 mg/kg bw/day in oral studies, and 20 to 200 mg/kg bw/day in dermal studies) (CLP Regulation (EC) no. 1272/2008: Annex 1, Part 3, Table 3.9.3).
The 90-day guidance values can be used as a basis to extrapolate equivalent guidance values for toxicity studies of greater or lesser duration, using dose/exposure time extrapolation similar to Haber’s rule for inhalation, which states essentially that the effective dose is directly proportional to the exposure concentration and the duration of exposure. The assessment shall be done on a case-by-case basis; for a 28-day study the guidance values below is increased by a factor of three. Based on this relation, the equivalent guidance value calculated for a 50-day study results to be approximately 180 mg/kg bw/day. Therefore, starting from the lowest available NOAEL of 100 mg/kg for general toxicity to females obtained during the OECD 421 study (exposure of approx. 50 days), a LOAEL of 300 mg/kg bw/day can be considered. This value results to be above the calculated equivalent guidance value (50 day-exposure). Therefore, no classification of the substance is warranted for specific target organ toxicity: repeated exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.